Business Wire

Northern Data AG Sees Substantial Demand for Its Bitcoin Mining Services

Share

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) is currently seeing a substantial increase in demand for its bitcoin mining infrastructure services.

Bitcoin mining is the most important high-performance computing (HPC) application to date. Consequently, with its global infrastructure solutions in the field of HPC, Northern Data serves many customers in the field of bitcoin mining, including several multibillion-dollar listed corporations.

With the rise of Bitcoin as an essential asset class and the associated need for computing capacity for bitcoin mining, Northern Data benefits in two ways: First, the Company experiences a sharp increase in customer demand. Second, Northern Data has performance-linked remuneration in place with some of its clients, such that Northern Data is now directly profiting from the rise in the bitcoin price.

In addition to the existing facility in Texas, the capacities in the Lefdal mine in Norway, which launched in May 2018, are also about to be further expanded. And in Scandinavia alone, five new locations for high-performance computing and bitcoin mining are expected to begin operations over the coming months. Furthermore, multiple locations in North America, especially Canada, are in final stages of negotiation.

In addition to the further expansion of its bitcoin mining activities, the Company is also expanding into other applications of high-performance computing. The Company's GPU-based distributed computing cluster began operating earlier in December.

This GPU cluster will be scaled to computing power of 404 petaflops (FP64) by the end of Q1/2021, well ahead of the currently second fastest supercomputer in the world, the US "Summit", which has a computing power of 148.8 petaflops. Only the Japanese supercomputer Fugaku will be ahead of Northern Data's GPU cluster, at 537 petaflops.

CEO Aroosh Thillainathan comments: "With more than seven years of experience in bitcoin mining and innovative solutions for both mobile units and large-scale facilities, Northern Data has a technological edge over the competition like no other company in the market. This is the basis of our success. In addition to the basic remuneration model, our performance-driven revenues, with which we participate in a rising bitcoin price, give us additional upside that we have not yet taken into account in our guidance."

Earlier this week Northern Data released its guidance for the financial year 2021. The Company expects sales of EUR 350 million to EUR 400 million and EBITDA of EUR 100 million to EUR 125 million in 2021, based on contracts that have already been executed or are in the process of being concluded and without considering any additional upside from performance-linked revenues and earnings.

About Northern Data:

Northern Data AG develops and operates global infrastructure solutions in the field of high-performance computing (HPC). With its customer-specific solutions, the company provides the infrastructure for various HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company is today a leading provider of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. The company combines its self-developed software and hardware with a sustainable energy supply. The Northern Data group currently employs about 150 members of staff.

Disclaimer:

This press release does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to serve as a basis for financial, legal, tax or other business decisions. Investment or other decisions should not be based solely on this press release. As with all business and investment matters, please consult qualified professional advice.

Language:

English

Company:

Northern Data AG

 

Thurn-und-Taxis-Platz 6

 

60313 Frankfurt/Main

 

Germany

Phone:

+49 69 34 87 52 25

E-mail:

info@northerndata.de

Internet:

www.northerndata.de

ISIN:

DE000A0SMU87

WKN:

A0SMU8

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich (m:access), Stuttgart, Tradegate Exchange

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Northern Data AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
e-mail: hans.duerr@northerndata.de
Phone: +49 69 348 752 89

Investor Relations:
Sven Pauly
e-mail: ir@northerndata.de
Phone: +49 89 125 09 03 30

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release

With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye